{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:49:35Z","timestamp":1787161775480,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    <jats:bold>Background and Aims:<\/jats:bold>\n                    Patients with light-chain cardiac amyloidosis (AL-CA) are characterized by high levels of serum carbohydrate antigen 125 (CA 125). However, studies have not explored the correlation between CA 125 and AL-CA. The aim of this study was to explore the clinical implications of an increase in CA 125 in patients with AL-CA.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods and Results:<\/jats:bold>\n                    A total of 95 patients diagnosed with AL-CA at the Second Xiangya Hospital were enrolled in this study. Out of the 95 patients with AL-CA, 57 (60%) patients had elevated serum CA 125 levels. The mean age was 59.7 \u00b1 10.0 years with 44 (77.2%) men in the high serum CA 125 group, and 61.8 \u00b1 9.6 years with 28 (73.7%) men in the normal group. Patients with high CA 125 showed higher rates of polyserositis (79.3% vs. 60.5%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.03), higher levels of hemoglobin (117.4 \u00b1 21.9 g\/L vs. 106.08 \u00b1 25.1 g\/L,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.03), serum potassium (4.11 \u00b1 0.47 mmol\/L vs. 3.97 \u00b1 0.40 mmol\/L,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.049), low-density lipoprotein-cholesterol (3.0 \u00b1 1.6 mmol\/L vs. 2.3 \u00b1 1.10 mmol\/L,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01), and cardiac troponin T (96.0 pg\/mL vs. 91.9 pg\/mL,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.005). The median overall survival times for patients with high or normal serum CA 125 were 5 and 25 months, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.045). Multivariate Cox hazard analysis showed that treatment without chemotherapy (HR 1.694, 95% CI 1.121\u20132.562,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.012) and CA 125 (HR 1.002, 95% CI 1.000\u20131.004,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.020) was correlated with high all-cause mortality. The time-dependent receiver operating characteristic (t-ROC) curve showed that the prediction accuracy of CA 125 was not inferior to that of cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and lactate dehydrogenase (LDH) based on the area under the curve.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    CA 125 is a novel prognostic predictor. High serum CA 125 values are correlated with low overall survival, and the accuracy of predicting prognosis is similar to that of traditional biomarkers in AL-CA.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2021.692083","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T01:32:12Z","timestamp":1635384732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["High Serum Carbohydrate Antigen (CA) 125 Level Is Associated With Poor Prognosis in Patients With Light-Chain Cardiac Amyloidosis"],"prefix":"10.3389","volume":"8","author":[{"given":"Muzheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"Tudahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuzhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenghua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunLi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/JAHA.111.000364","article-title":"Updates in cardiac amyloidosis: a review","volume":"1","author":"Banypersad","year":"2012","journal-title":"J Am Heart Assoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet (London, England)."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Failure."},{"key":"B7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of biomarkers in cardiac amyloidosis. JACC","volume":"8","author":"Pregenzer-Wenzler","year":"","journal-title":"Heart Fail. (2"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/ajh.25576","article-title":"Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis","volume":"94","author":"Pudusseri","year":"2019","journal-title":"Am J Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.7150\/jca.30345","article-title":"High serum lactate dehydrogenase adds prognostic value to cardiac biomarker staging system for light chain amyloidosis","volume":"10","author":"He","year":"2019","journal-title":"J Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0028-2243(93)90135-Y","article-title":"CA 125 in gynecological pathology\u2014a review","volume":"49","author":"Kenemans","year":"1993","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0090-8258(92)90254-G","article-title":"Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125","volume":"46","author":"H\u00f6gberg","year":"1992","journal-title":"Gynecol Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejheart.2004.07.015","article-title":"The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters","volume":"7","author":"Kouris","year":"2005","journal-title":"Eur J Heart Fail."},{"key":"B13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ejheart.2008.04.012","article-title":"Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume","volume":"10","author":"Duman","year":"2008","journal-title":"Eur J Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/S0735-1097(03)00311-5","article-title":"Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis","volume":"41","author":"D'Aloia","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ejheart.2004.12.008","article-title":"Tumour marker levels in patients with chronic heart failure","volume":"7","author":"Varol","year":"2005","journal-title":"Eur J Heart Fail."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0002-8703(99)70360-1","article-title":"CA 125 and its relation to cardiac function","volume":"137","author":"N\u00e4gele","year":"1999","journal-title":"Am Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/jama.277.11.925","article-title":"Recommendations guiding physicians in biomedical research involving human subjects","volume":"277","year":"1997","journal-title":"JAMA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/bjc.1984.254","article-title":"Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker","volume":"50","author":"Canney","year":"1984","journal-title":"Br J Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7326\/0003-4819-115-8-623","article-title":"Clinical applications of serum tumor markers","volume":"115","author":"Bates","year":"1991","journal-title":"Ann Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/(sici)1097-0142(20000101)88:1<75::aid-cncr11>3.0.co;2-#","article-title":"Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement","volume":"88","author":"Camera","year":"2000","journal-title":"Cancer Am Cancer Soc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/CBM-160632","article-title":"Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma","volume":"17","author":"Wu","year":"2016","journal-title":"Cancer Biomark Sect A Dis Mark."},{"key":"B22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/gut.28.3.323","article-title":"Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system","volume":"28","author":"Sakamoto","year":"1987","journal-title":"GUT."},{"key":"B23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41419-020-03067-8","article-title":"ERO1L promotes IL6\/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells","volume":"11","author":"Lei","year":"2020","journal-title":"Cell Death Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/annonc\/mdr154","article-title":"Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome","volume":"23","author":"Yerushalmi","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"B25","first-page":"407","article-title":"Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer","volume":"168","author":"Talbot","year":"1989","journal-title":"Surg Gynecol Obstet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4065\/77.6.538","article-title":"Cancer antigen 125 in patients with chronic liver disease","volume":"77","author":"Devarbhavi","year":"2002","journal-title":"Mayo Clin Proc."},{"key":"B27","first-page":"1327","article-title":"Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy","volume":"57","author":"Halila","year":"1986","journal-title":"Cancer Am Cancer Soc."},{"key":"B28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.gie.2008.03.1079","article-title":"Laparoscopic appearance in a case of peritoneal tuberculosis with elevated cancer antigen 125 levels","volume":"69","author":"Shin","year":"2009","journal-title":"Gastrointest Endosc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1253\/jcj.57.489","article-title":"Usefulness of serum CA125 measurement for monitoring pericardial effusion","volume":"57","author":"Seo","year":"1993","journal-title":"Jpn Circ J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/eurheartj\/ehq142","article-title":"Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure","volume":"31","author":"N\u00fa\u00f1ez","year":"2010","journal-title":"Eur Heart J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood."},{"key":"B33","first-page":"213","article-title":"Elevation of CA 125 in patients with benign and malignant ascites","volume":"59","author":"Bergmann","year":"1987","journal-title":"Cancer Am Cancer Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/humrep\/15.6.1261","article-title":"CA125 production by the peritoneum: in-vitro and in-vivo studies","volume":"15","author":"Epiney","year":"2000","journal-title":"Hum Reprod (Oxford, England)."},{"key":"B35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1006\/gyno.2000.5776","article-title":"Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids","volume":"77","author":"Sevinc","year":"2000","journal-title":"Gynecol Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejheart.2005.09.002","article-title":"Relationship between cytokines and tumour markers in patients with chronic heart failure","volume":"8","author":"Kosar","year":"2006","journal-title":"Eur J Heart Fail."},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cyto.2018.07.037","article-title":"NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure","volume":"111","author":"Stanciu","year":"2018","journal-title":"Cytokine."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1006\/gyno.1999.5670","article-title":"Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites","volume":"20","author":"Sevinc","year":"2000","journal-title":"Anticancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jchf.2016.06.007","article-title":"Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC","volume":"4","author":"N\u00fa\u00f1ez","year":"2016","journal-title":"Heart Fail."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.692083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T01:32:16Z","timestamp":1635384736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.692083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2021.692083"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.692083","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"692083"}}